RBC Capital on Boston Scientific (BSX): 'Consistent Top Performer That Isn't Slowing Down'

RBC Capital analyst Shagun Singh reiterated an Outperform rating and $105.00 price target on Boston Scientific (NYSE: BSX).

The analyst commented: "BSX: Consistent Top Performer That Isn't Slowing Down. We caught up with BSX (1/16) to discuss its operational focus and catalysts in 2025, latest M&A (note here), and takeaways from conversations with investors this week. Overall, we have come away more bullish on the company's 2025 set-up with increasing WAMGR (now 8% in 2024 and 9% in 2026), multiple growth catalysts (e.g., PFA where BSX is targeting to be a category leader, LAAC with significant runway ahead), and strong margin/EPS growth profile. We see substantial upside to consensus estimates as we move through the year and reiterate our Outperform rating."

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $98.17 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• AI/ML Innovations plans $2M private placement on the CSE
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery